PT1075281E - Conjugados poliol-ifn-beta - Google Patents

Conjugados poliol-ifn-beta

Info

Publication number: PT1075281E
Authority: PT; Portugal
Prior art keywords: beta; ifn; conjugates; peg; poliol
Prior art date: 1998-04-28

Application number

PT99920094T

Other languages

English (en)

Inventor

Milton Harris

Nabil El Tayar

Michael J Roberts

Wayne Sawlivich

Original Assignee

Applied Research Systems

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-04-28

Filing date

1999-04-28

Publication date

2004-11-30

1999-04-28 Application filed by Applied Research Systems filed Critical Applied Research Systems

2004-11-30 Publication of PT1075281E publication Critical patent/PT1075281E/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Epidemiology (AREA)
Virology (AREA)
Rheumatology (AREA)
Toxicology (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Transplantation (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PT99920094T 1998-04-28 1999-04-28 Conjugados poliol-ifn-beta PT1075281E (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US8333998P	1998-04-28	1998-04-28

Publications (1)

Publication Number	Publication Date
PT1075281E true PT1075281E (pt)	2004-11-30

Family

ID=22177687

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PT99920094T PT1075281E (pt)	1998-04-28	1999-04-28	Conjugados poliol-ifn-beta
PT04003053T PT1421956E (pt)	1998-04-28	1999-04-28	Processo para a ligação por passos de polietileno glicol ( peg ) a um polipéptido

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PT04003053T PT1421956E (pt)	1998-04-28	1999-04-28	Processo para a ligação por passos de polietileno glicol ( peg ) a um polipéptido

Country Status (30)

Country	Link
US (3)	US6638500B1 (pt)
EP (2)	EP1421956B1 (pt)
JP (2)	JP4574007B2 (pt)
KR (1)	KR100622796B1 (pt)
CN (2)	CN1187094C (pt)
AR (1)	AR020070A1 (pt)
AT (2)	ATE275422T1 (pt)
AU (1)	AU762621B2 (pt)
BG (2)	BG65046B1 (pt)
BR (1)	BR9910023A (pt)
CA (2)	CA2330451A1 (pt)
CY (1)	CY1108022T1 (pt)
CZ (2)	CZ298579B6 (pt)
DE (2)	DE69920002T2 (pt)
DK (2)	DK1421956T3 (pt)
EA (2)	EA200300382A1 (pt)
EE (1)	EE05214B1 (pt)
ES (2)	ES2224649T3 (pt)
HU (1)	HUP0300548A3 (pt)
IL (1)	IL139286A (pt)
NO (2)	NO329749B1 (pt)
NZ (1)	NZ507456A (pt)
PL (2)	PL193352B1 (pt)
PT (2)	PT1075281E (pt)
SI (2)	SI1075281T1 (pt)
SK (2)	SK286217B6 (pt)
TR (2)	TR200003161T2 (pt)
TW (2)	TWI266800B (pt)
UA (2)	UA66857C2 (pt)
WO (1)	WO1999055377A2 (pt)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5932462A (en)	1995-01-10	1999-08-03	Shearwater Polymers, Inc.	Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US7704944B2 (en)	1997-08-14	2010-04-27	Yeda Research And Development Company Ltd.	Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis
IL121860A0 (en)	1997-08-14	1998-02-22	Yeda Res & Dev	Interleukin-18 binding proteins their preparation and use
US7220717B2 (en)	1997-08-14	2007-05-22	Yeda Research And Development Company Ltd.	Interleukin-18 binding proteins, their preparation and use
HK1042098B (zh)	1998-10-16	2009-10-30	拜奥根Idec马萨诸塞公司	干扰素-β融合蛋白及用途
TR200101086T2 (tr) *	1998-10-16	2001-08-21	Biogen, Inc.	Interferon beta-1A'nın polimer birleşikleri ve kullanımları.
EP1880736A1 (en) *	1999-04-23	2008-01-23	Alza Corporation	Releasable linkage and composition containing same
US7238368B2 (en) *	1999-04-23	2007-07-03	Alza Corporation	Releasable linkage and compositions containing same
US7303760B2 (en) *	1999-04-23	2007-12-04	Alza Corporation	Method for treating multi-drug resistant tumors
US6531122B1 (en)	1999-08-27	2003-03-11	Maxygen Aps	Interferon-β variants and conjugates
US7144574B2 (en)	1999-08-27	2006-12-05	Maxygen Aps	Interferon β variants and conjugates
US7431921B2 (en)	1999-08-27	2008-10-07	Maxygen Aps	Interferon beta-like molecules
TR200101086A3 (pt) *	1999-10-15	2001-08-21
JP4593048B2 (ja)	1999-12-24	2010-12-08	協和発酵キリン株式会社	分岐型ポリアルキレングリコール類
AU782580B2 (en)	2000-01-10	2005-08-11	Maxygen, Inc.	G-CSF conjugates
ATE428445T1 (de)	2000-02-11	2009-05-15	Bayer Healthcare Llc	Gerinnungsfaktor vii oder viia konjugate
ATE471956T1 (de) *	2001-01-30	2010-07-15	Kyowa Hakko Kirin Co Ltd	Verzweigte polyalkylenglykole
EP1234583A1 (en)	2001-02-23	2002-08-28	F. Hoffmann-La Roche Ag	PEG-conjugates of HGF-NK4
BR0207576A (pt)	2001-02-27	2004-04-27	Maxygen Aps	Variante glicosilada de um polipeptìdeo de interferon beta precursor (ifnb), processos de aumentar a glicosilação in vivo de uma molécula de ifnb precursora, de produzir uma molécula de ifnb glicosilada, para preparar uma variante conjugada e de tratar um mamìfero com esclerose múltiplam composição farmacêutica, molécula de ifnb variante, sequência de nucleotìdeo, vetor de expressão, célula hospedeira de glicosilação conjugado, e, uso de um conjugado
WO2003006501A2 (en)	2001-07-11	2003-01-23	Maxygen Holdings, Ltd.	G-csf conjugates
NZ534708A (en)	2002-01-18	2007-05-31	Biogen Idec Inc	Polyalkylene glycol with moiety for conjugating biologically active compound
TWI334785B (en)	2002-06-03	2010-12-21	Serono Lab	Use of recombinant ifn-β1a and pharmaceutical composition comprising recombinant ifn-β1a for the treatment of hcv infection in patients of asian race
WO2004020468A2 (en) *	2002-08-28	2004-03-11	Maxygen Aps	Interferon beta-like molecules for treatment of cancer
US8129330B2 (en) *	2002-09-30	2012-03-06	Mountain View Pharmaceuticals, Inc.	Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
CN102319437B (zh)	2002-12-26	2017-10-13	山景医药公司	具有增强的生物学效用的干扰素‑β的聚合物缀合物
GEP20084487B (en) *	2002-12-26	2008-09-25	Mountain View Pharmaceuticals	Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof
EP2085470B1 (en)	2003-03-20	2012-05-16	Bayer HealthCare LLC	FVII or FVIIa variants
TWI272948B (en)	2003-05-01	2007-02-11	Ares Trading Sa	HSA-free stabilized interferon liquid formulations
GB0316294D0 (en)	2003-07-11	2003-08-13	Polytherics Ltd	Conjugated biological molecules and their preparation
ES2428358T3 (es)	2003-10-17	2013-11-07	Novo Nordisk A/S	Terapia de combinación
AU2008201682B2 (en) *	2004-02-02	2011-02-24	Ambrx, Inc.	Modified human interferon polypeptides and their uses
CA2553035A1 (en)	2004-02-02	2005-08-18	Ambrx, Inc.	Modified human growth hormone polypeptides and their uses
EP1586334A1 (en) *	2004-04-15	2005-10-19	TRASTEC scpa	G-CSF conjugates with peg
WO2005110466A1 (en)	2004-05-17	2005-11-24	Ares Trading S.A.	Hydrogel interferon formulations
US7731948B2 (en)	2004-06-01	2010-06-08	Ares Trading S.A.	Stabilized interferon liquid formulations
JP2008500995A (ja)	2004-06-01	2008-01-17	アレストレーディングソシエテアノニム	タンパク質安定化法
TW200633718A (en) *	2004-12-16	2006-10-01	Applied Research Systems	Treatment of hepatitis c in the asian population
ATE494012T1 (de)	2004-12-21	2011-01-15	Nektar Therapeutics	Stabilisierte polymer-thiol-reagenzien
ATE542920T1 (de)	2004-12-22	2012-02-15	Ambrx Inc	Modifiziertes menschliches wachstumshormon
BRPI0518661A2 (pt)	2004-12-22	2008-12-02	Ambrx Inc	mÉtodos para expressço e purificaÇço do hormânio do crescimento humano recombinante
BRPI0519170A8 (pt)	2004-12-22	2018-05-08	Ambrx Inc	formulações de hormônio de crescimento humano que compreendem um aminoácido não naturalmente codificado
EP1893632B1 (en)	2005-06-17	2015-08-12	Novo Nordisk Health Care AG	Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine
MX2008001706A (es) *	2005-08-04	2008-04-07	Nektar Therapeutics Al Corp	Conjugados de una porcion g-csf y un polimero.
RS57549B1 (sr)	2005-08-26	2018-10-31	Ares Trading Sa	Proces za pripremu glikoziliranog interferona beta
AU2006286489B2 (en)	2005-09-01	2012-08-09	Ares Trading S.A.	Treatment of optic neuritis
US20070238656A1 (en) *	2006-04-10	2007-10-11	Eastman Kodak Company	Functionalized poly(ethylene glycol)
US20080096819A1 (en) *	2006-05-02	2008-04-24	Allozyne, Inc.	Amino acid substituted molecules
US7632492B2 (en) *	2006-05-02	2009-12-15	Allozyne, Inc.	Modified human interferon-β polypeptides
EP2213733A3 (en)	2006-05-24	2010-12-29	Novo Nordisk Health Care AG	Factor IX analogues having prolonged in vivo half life
CA2649810A1 (en)	2006-05-24	2007-11-29	Laboratoires Serono S.A.	Cladribine regimen for treating multiple sclerosis
WO2008137471A2 (en) *	2007-05-02	2008-11-13	Ambrx, Inc.	Modified interferon beta polypeptides and their uses
CA2707840A1 (en) *	2007-08-20	2009-02-26	Allozyne, Inc.	Amino acid substituted molecules
AU2008340058A1 (en) *	2007-12-20	2009-07-02	Merck Serono S.A.	PEG-interferon-beta formulations
SG188143A1 (en)	2008-02-08	2013-03-28	Ambrx Inc	Modified leptin polypeptides and their uses
CN101525381B (zh) *	2008-03-04	2012-04-18	北京百川飞虹生物科技有限公司	一种重组复合干扰素及其表达载体的构建和表达
WO2009155102A2 (en) *	2008-05-30	2009-12-23	Barofold, Inc.	Method for derivatization of proteins using hydrostatic pressure
US20110124614A1 (en) *	2008-10-25	2011-05-26	Halina Offner	Methods And Compositions For The Treatment of Autoimmune Disorders
DE102009032179A1 (de) *	2009-07-07	2011-01-13	Biogenerix Ag	Verfahren zur Reinigung von Interferon beta
ES2365343B1 (es)	2009-11-19	2012-07-10	Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii	Uso de cd98 como marcador de receptividad endometrial.
WO2011101242A1 (en)	2010-02-16	2011-08-25	Novo Nordisk A/S	Factor viii molecules with reduced vwf binding
AR080993A1 (es)	2010-04-02	2012-05-30	Hanmi Holdings Co Ltd	Formulacion de accion prolongada de interferon beta donde se usa un fragmento de inmunoglobulina
EP3372617B1 (en)	2010-04-02	2024-07-24	Amunix Pharmaceuticals, Inc.	Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
WO2011143274A1 (en)	2010-05-10	2011-11-17	Perseid Therapeutics	Polypeptide inhibitors of vla4
WO2012007324A2 (en)	2010-07-15	2012-01-19	Novo Nordisk A/S	Stabilized factor viii variants
WO2012035050A2 (en)	2010-09-15	2012-03-22	Novo Nordisk A/S	Factor viii variants having a decreased cellular uptake
EP3395356B1 (en) *	2011-02-18	2021-05-19	Stemdr Inc.	Composition containing inducer of sirt1 expression for preventing or treating sepsis or septic shock
CN103930440A (zh)	2011-07-01	2014-07-16	拜耳知识产权有限责任公司	松弛素融合多肽及其用途
SG10201602076QA (en) *	2011-10-01	2016-04-28	Glytech Inc	Glycosylated polypeptide and pharmaceutical composition containing same
WO2013130683A2 (en)	2012-02-27	2013-09-06	Amunix Operating Inc.	Xten conjugate compositions and methods of making same
CN104136038A (zh)	2012-02-29	2014-11-05	东丽株式会社	体腔积液抑制剂
DK2982686T3 (en)	2013-03-29	2018-10-08	Glytech Inc	POLYPEPTIDE WITH SIALYLED SUGAR CHAIN CONNECTED
WO2016013697A1 (ko) *	2014-07-24	2016-01-28	에이비온 주식회사	인터페론-베타 변이체의 폴리에틸렌글리콜 배합체
KR101671501B1 (ko) *	2014-07-24	2016-11-03	에이비온 주식회사	페길화된 인터페론-베타 변이체
RS61128B1 (sr)	2014-08-19	2020-12-31	Biogen Ma Inc	Postupak pegilacije
EP3288577B1 (en)	2015-05-01	2021-10-27	Allysta Pharmaceuticals, Inc.	Adiponectin peptidomimetics for treating ocular disorders
HUE051315T2 (hu) *	2015-06-19	2021-03-01	Eisai R&D Man Co Ltd	Cys80 helyzetben konjugált immunglobulinok
HRP20241491T1 (hr)	2015-11-09	2025-01-03	The Regents Of The University Of Colorado, A Body Corporate	Pripravci i metode za liječenje homocistinurije
JP7146897B2 (ja) *	2017-04-17	2022-10-04	ザリージェンツオブザユニバーシティオブコロラド，アボディーコーポレイト	ホモシスチン尿症の治療のための酵素補充療法の最適化
SG11202004772RA (en)	2017-11-24	2020-06-29	Merck Patent Gmbh	Cladribine regimen for use intreating progressive forms of multiple sclerosis
BR112021012472A2 (pt)	2019-01-28	2021-11-30	Toray Industries	Forma modificada por polietileno glicol de um fator de crescimento de hepatócito ou um fragmento ativo do mesmo, e, medicamento
US20220118050A1 (en)	2019-01-28	2022-04-21	Toray Industries, Inc.	Polyethylene glycol-modified form of hepatocyte growth factor or active fragment thereof
KR20230066402A (ko)	2020-09-10	2023-05-15	메르크 파텐트 게엠베하	자가면역 장애의 치료를 위한 신규 치료 용법

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4766106A (en)	1985-06-26	1988-08-23	Cetus Corporation	Solubilization of proteins for pharmaceutical compositions using polymer conjugation
DE3676670D1 (de) *	1985-06-26	1991-02-07	Cetus Corp	Solubilisierung von proteinen fuer pharmazeutische zusammensetzungen mittels polymerkonjugierung.
US5206344A (en) *	1985-06-26	1993-04-27	Cetus Oncology Corporation	Interleukin-2 muteins and polymer conjugation thereof
US4917888A (en)	1985-06-26	1990-04-17	Cetus Corporation	Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US5208344A (en) *	1987-07-31	1993-05-04	American Home Products Corporation	Naphthalenepropionic acid derivatives as anti-inflammatory/antiallergic agents
US5166322A (en) *	1989-04-21	1992-11-24	Genetics Institute	Cysteine added variants of interleukin-3 and chemical modifications thereof
US5595732A (en) *	1991-03-25	1997-01-21	Hoffmann-La Roche Inc.	Polyethylene-protein conjugates
US5382657A (en)	1992-08-26	1995-01-17	Hoffmann-La Roche Inc.	Peg-interferon conjugates
KR960705579A (ko)	1993-11-10	1996-11-08	에릭에스. 딕커	개선된 인터페론 중합체 결합체(Improved interferon polymer conjugates)
US5766581A (en)	1994-03-31	1998-06-16	Amgen Inc.	Method for treating mammals with monopegylated proteins that stimulates megakaryocyte growth and differentiation
MX9605717A (es) *	1994-05-18	1998-05-31	Inhale Therapeutic Syst	Metodos y composiciones para la formulacion de polvo seco de interferones.
US5824784A (en) *	1994-10-12	1998-10-20	Amgen Inc.	N-terminally chemically modified protein compositions and methods
US5932462A (en)	1995-01-10	1999-08-03	Shearwater Polymers, Inc.	Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
SE9503380D0 (sv) *	1995-09-29	1995-09-29	Pharmacia Ab	Protein derivatives
TW517067B (en) *	1996-05-31	2003-01-11	Hoffmann La Roche	Interferon conjugates
US5851984A (en) *	1996-08-16	1998-12-22	Genentech, Inc.	Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
KR0176625B1 (ko)	1996-11-05	1999-04-01	삼성전자주식회사	적외선 물체검출장치
WO1998032466A1 (en) *	1997-01-29	1998-07-30	Polymasc Pharmaceuticals Plc	Pegylation process
CA2296770A1 (en) *	1997-07-14	1999-01-28	Bolder Biotechnology, Inc.	Derivatives of growth hormone and related proteins
US6307024B1 (en) *	1999-03-09	2001-10-23	Zymogenetics, Inc.	Cytokine zalpha11 Ligand
US6531122B1 (en) *	1999-08-27	2003-03-11	Maxygen Aps	Interferon-β variants and conjugates

1999
- 1999-04-28 KR KR1020007011587A patent/KR100622796B1/ko not_active Expired - Fee Related
- 1999-04-28 TR TR2000/03161T patent/TR200003161T2/xx unknown
- 1999-04-28 BR BR9910023-1A patent/BR9910023A/pt active Search and Examination
- 1999-04-28 CN CNB998054968A patent/CN1187094C/zh not_active Expired - Fee Related
- 1999-04-28 SK SK1622-2000A patent/SK286217B6/sk not_active IP Right Cessation
- 1999-04-28 CZ CZ20003995A patent/CZ298579B6/cs not_active IP Right Cessation
- 1999-04-28 SK SK66-2007A patent/SK286654B6/sk not_active IP Right Cessation
- 1999-04-28 CN CNB2004100898478A patent/CN100335503C/zh not_active Expired - Fee Related
- 1999-04-28 UA UA2000116719A patent/UA66857C2/uk unknown
- 1999-04-28 WO PCT/US1999/009161 patent/WO1999055377A2/en not_active Ceased
- 1999-04-28 DE DE69920002T patent/DE69920002T2/de not_active Expired - Lifetime
- 1999-04-28 HU HU0300548A patent/HUP0300548A3/hu unknown
- 1999-04-28 DK DK04003053T patent/DK1421956T3/da active
- 1999-04-28 TR TR2001/01751T patent/TR200101751T2/xx unknown
- 1999-04-28 AT AT99920094T patent/ATE275422T1/de active
- 1999-04-28 CZ CZ20050048A patent/CZ298597B6/cs not_active IP Right Cessation
- 1999-04-28 JP JP2000545574A patent/JP4574007B2/ja not_active Expired - Lifetime
- 1999-04-28 PT PT99920094T patent/PT1075281E/pt unknown
- 1999-04-28 EP EP04003053A patent/EP1421956B1/en not_active Expired - Lifetime
- 1999-04-28 NZ NZ507456A patent/NZ507456A/en not_active IP Right Cessation
- 1999-04-28 PL PL344490A patent/PL193352B1/pl not_active IP Right Cessation
- 1999-04-28 AT AT04003053T patent/ATE365563T1/de active
- 1999-04-28 CA CA002330451A patent/CA2330451A1/en not_active Abandoned
- 1999-04-28 EE EEP200000614A patent/EE05214B1/xx not_active IP Right Cessation
- 1999-04-28 CA CA002565375A patent/CA2565375A1/en not_active Abandoned
- 1999-04-28 IL IL13928699A patent/IL139286A/xx not_active IP Right Cessation
- 1999-04-28 EA EA200300382A patent/EA200300382A1/ru not_active IP Right Cessation
- 1999-04-28 ES ES99920094T patent/ES2224649T3/es not_active Expired - Lifetime
- 1999-04-28 SI SI9930662T patent/SI1075281T1/xx unknown
- 1999-04-28 PT PT04003053T patent/PT1421956E/pt unknown
- 1999-04-28 DK DK99920094T patent/DK1075281T3/da active
- 1999-04-28 AU AU37674/99A patent/AU762621B2/en not_active Ceased
- 1999-04-28 EA EA200001111A patent/EA003789B1/ru not_active IP Right Cessation
- 1999-04-28 PL PL378728A patent/PL196533B1/pl not_active IP Right Cessation
- 1999-04-28 EP EP99920094A patent/EP1075281B1/en not_active Expired - Lifetime
- 1999-04-28 UA UA20031212655A patent/UA79430C2/uk unknown
- 1999-04-28 SI SI9930974T patent/SI1421956T1/sl unknown
- 1999-04-28 ES ES04003053T patent/ES2285286T3/es not_active Expired - Lifetime
- 1999-04-28 DE DE69936409T patent/DE69936409T2/de not_active Expired - Lifetime
- 1999-04-29 AR ARP990101987A patent/AR020070A1/es active IP Right Grant
- 1999-07-26 TW TW093123043A patent/TWI266800B/zh active
- 1999-07-26 TW TW088112596A patent/TWI232882B/zh active
2000
- 2000-10-17 BG BG109291A patent/BG65046B1/bg unknown
- 2000-10-17 BG BG104871A patent/BG64694B1/bg unknown
- 2000-10-23 NO NO20005337A patent/NO329749B1/no not_active IP Right Cessation
- 2000-10-30 US US09/698,133 patent/US6638500B1/en not_active Expired - Lifetime
2003
- 2003-08-28 US US10/649,609 patent/US7357925B2/en not_active Expired - Fee Related
2007
- 2007-02-13 US US11/674,476 patent/US7700314B2/en not_active Expired - Fee Related
- 2007-07-19 CY CY20071100966T patent/CY1108022T1/el unknown
2010
- 2010-03-09 NO NO20100324A patent/NO332224B1/no not_active IP Right Cessation
- 2010-04-26 JP JP2010100840A patent/JP2010184929A/ja active Pending

Also Published As

Publication number	Publication date
TR200003161T2 (tr)	2001-01-22
TWI266800B (en)	2006-11-21
PL193352B1 (pl)	2007-02-28
JP2002512983A (ja)	2002-05-08
UA79430C2 (en)	2007-06-25
DE69920002T2 (de)	2005-09-22
ES2285286T3 (es)	2007-11-16
CZ298579B6 (cs)	2007-11-14
ES2224649T3 (es)	2005-03-01
SI1421956T1 (sl)	2007-10-31
ATE365563T1 (de)	2007-07-15
PL344490A1 (en)	2001-11-05
AU3767499A (en)	1999-11-16
JP4574007B2 (ja)	2010-11-04
US7700314B2 (en)	2010-04-20
SK16222000A3 (sk)	2001-04-09
SK286654B6 (sk)	2009-03-05
CN1187094C (zh)	2005-02-02
PL196533B1 (pl)	2008-01-31
EP1075281A2 (en)	2001-02-14
NO332224B1 (no)	2012-07-30
PT1421956E (pt)	2007-07-13
US20040043002A1 (en)	2004-03-04
BG65046B1 (bg)	2007-01-31
CA2565375A1 (en)	1999-11-04
CZ20003995A3 (en)	2001-06-13
SK286217B6 (sk)	2008-05-06
EA005495B1 (ru)	2005-02-24
NO20100324L (no)	2000-12-28
NO329749B1 (no)	2010-12-13
KR100622796B1 (ko)	2006-09-13
EA200300382A1 (ru)	2005-02-24
EA200001111A1 (ru)	2001-04-23
ATE275422T1 (de)	2004-09-15
CN1302209A (zh)	2001-07-04
IL139286A (en)	2005-12-18
AU762621B2 (en)	2003-07-03
AR020070A1 (es)	2002-04-10
NO20005337D0 (no)	2000-10-23
CY1108022T1 (el)	2013-09-04
BG109291A (en)	2006-04-28
DE69936409T2 (de)	2008-04-17
BR9910023A (pt)	2000-12-26
HUP0300548A3 (en)	2005-07-28
DK1421956T3 (da)	2007-10-01
CN100335503C (zh)	2007-09-05
US7357925B2 (en)	2008-04-15
NO20005337L (no)	2000-12-28
TR200101751T2 (tr)	2002-05-21
DE69936409D1 (de)	2007-08-09
CA2330451A1 (en)	1999-11-04
DE69920002D1 (de)	2004-10-14
JP2010184929A (ja)	2010-08-26
WO1999055377A3 (en)	1999-12-29
WO1999055377A2 (en)	1999-11-04
KR20010071158A (ko)	2001-07-28
HUP0300548A2 (hu)	2003-06-28
CN1637020A (zh)	2005-07-13
BG64694B1 (bg)	2005-12-30
US20070141620A1 (en)	2007-06-21
SI1075281T1 (en)	2005-02-28
US6638500B1 (en)	2003-10-28
HK1076115A1 (en)	2006-01-06
BG104871A (en)	2001-07-31
EP1421956A1 (en)	2004-05-26
HK1038194A1 (en)	2002-03-08
TWI232882B (en)	2005-05-21
CZ298597B6 (cs)	2007-11-21
NZ507456A (en)	2003-10-31
EP1421956B1 (en)	2007-06-27
EA003789B1 (ru)	2003-10-30
DK1075281T3 (da)	2005-01-03
EE200000614A (et)	2002-04-15
WO1999055377A9 (en)	2000-03-02
EE05214B1 (et)	2009-10-15
EP1075281B1 (en)	2004-09-08
IL139286A0 (en)	2001-11-25
UA66857C2 (uk)	2004-06-15

Publication	Publication Date	Title
PT1075281E (pt)	2004-11-30	Conjugados poliol-ifn-beta
WO2006004959A3 (en)	2006-09-28	Pegylated interferon alpha-1b
CA2158054A1 (en)	1994-10-13	Conjugates of proteins and bifunctional ligands
LU92237I2 (fr)	2013-09-03	Pegloticase et toute forme thérapeutique équivalente protégée par le brevet de base
NO901986D0 (no)	1990-05-04	Nytt antistoff-leveringssystem for biologisk respons-modifiserende midler.
DE69925830D1 (de)	2005-07-21	Peg-lhrh analog konjugate
CA2345027A1 (en)	2000-04-20	Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
BR9303469A (pt)	1994-03-22	Conjugado de interferon,composto,processo de preparacao de um conjugado de interferon,use e composicoes farmaceuticas
WO2003022210A3 (en)	2003-12-18	Pharmaceutical compositions of drug-oligomer conjugates and methods of treating diseases therewith
ATE335719T1 (de)	2006-09-15	Polyamine und ihre therapeutische verwendung
ATE469166T1 (de)	2010-06-15	Chemisch modifizierte polypeptide
PT88275A (pt)	1989-06-30	Processo para a preparacao de composicoes farmaceuticas contendo 5-amino ou amino substituido-1,2,3-triazois uteis como agentes antiproliferativos
DE3789788D1 (de)	1994-06-16	Aminderivate von Folsäure Analogen.
HU911929D0 (en)	1991-12-30	Process for the production of conjugates containing orto ligating functional group from chelate complexes and joint antibodies or antibody fragments and the medical preparations containing thereof
TR200003144T2 (tr)	2001-03-21	Tiyenopirimidinler.
TWI266801B (en)	2006-11-21	Polyol-IFN-beta conjugates
ATE249243T1 (de)	2003-09-15	Biotinylierter antikörper mit verminderter positiver nettoladung und toxin, medikament oder chelat
FI933506A0 (fi)	1993-08-09	Bicyklopolyazamakrocyklokarboxylsyrakomplex, konjugat daerav, foerfarande foer deras framstaellning och anvaendning som kontrastmedel
RU93053897A (ru)	1996-10-10	Комплексы бициклополиазамакроциклокарбоновых кислот, их конъюгаты, фармацевтическая композиция, способ диагностики, набор и способ получения